Who Owns Voltaren?
Voltaren is owned by Haleon plc, an independent publicly traded consumer health company listed on the London Stock Exchange and New York Stock Exchange (LSE/NYSE: HLN). Haleon was formed from the consumer health joint venture of GSK and Pfizer and began trading as an independent company in July 2022. In full-year 2025, Voltaren grew mid-single digit, supported by innovation launches including new format patches and the rollout of Voltadexibu in Germany and Italy. Haleon is headquartered in Weybridge, United Kingdom.
Parent Company
Haleon plc
Founded
1976
Status
Publicly Traded
Headquarters
Weybridge, United Kingdom
Who Owns Voltaren?
- Parent Company: Haleon plc
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: LSE: HLN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Voltaren | Haleon plc | Wholly owned |
History of Voltaren
- Founded: 1976
- Founders: Novartis (internal development)
Voltaren was developed by Novartis through extensive research into nonsteroidal anti-inflammatory drugs. The drug was approved in 1976 as a prescription pain relief and anti-inflammatory medication. Voltaren represented an important advancement in pain management, offering patients effective relief from various pain conditions.
Throughout the 1980s and 1990s, Voltaren expanded its product line to include topical formulations, making it available as a gel and cream for localized pain relief. The brand became known for its effectiveness in treating arthritis, muscle pain, and other inflammatory conditions. Voltaren quickly became one of the most popular pain relief medications globally.
Voltaren's product line expanded to include oral tablets, topical gels, and patches for different pain types and preferences. The brand became trusted by consumers for treating arthritis, back pain, muscle strains, and other pain conditions. Voltaren maintained its position as one of the leading pain relief brands globally.
Voltaren became part of Haleon when the consumer health joint venture of GSK and Pfizer was demerged and listed as an independent company in July 2022. Under Haleon's ownership, Voltaren has continued to grow. In full-year 2025, Voltaren grew mid-single digit, supported by innovation launches including new format patches and the rollout of Voltadexibu, a new API formulation providing effective treatment with a smaller dose, in Germany and Italy.
About Haleon plc
What does Haleon own?
Haleon owns a portfolio of approximately 24 global and regional consumer health brands across five categories: oral health, vitamins and supplements, pain relief, respiratory health, and digestive health. Key brands include Sensodyne (sensitivity toothpaste), Panadol (pain relief), Centrum (multivitamins), Advil (ibuprofen), Voltaren (topical pain relief), Otrivin (nasal decongestant), Parodontax (gum health), Polident and Poligrip (denture care), Aquafresh (oral care), and Emergen-C (vitamin C). Products are sold in more than 170 countries.
Is Haleon publicly traded?
Yes, Haleon plc is listed on the London Stock Exchange under ticker HLN, with American Depositary Shares also listed on the New York Stock Exchange under the same ticker. Haleon completed its listing on the London Stock Exchange on 18 July 2022, in what was the largest London Stock Exchange listing in over a decade. The company does not have a controlling shareholder, and its shares are held primarily by institutional investors.
Who founded Haleon?
Haleon was formed through the demerger of GSK's consumer healthcare division in July 2022 and does not have a traditional founder. The consumer healthcare business that became Haleon was assembled by GSK and Pfizer through decades of acquisitions. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, which was subsequently demerged as Haleon in 2022. Brian McNamara, who had led the GSK Consumer Healthcare joint venture, became CEO of Haleon at the time of the demerger.
Where is Haleon headquartered?
Haleon is headquartered in Weybridge, Surrey, United Kingdom. The company's registered office and principal executive offices are located in Weybridge. Haleon operates manufacturing facilities in the United Kingdom, the United States, India, Germany, Ireland, and China, among other locations. The company sells products in more than 170 countries through a global commercial organization.
How many brands does Haleon own?
Haleon owns approximately 24 global and regional consumer health brands. The company's portfolio is concentrated in five categories: oral health (Sensodyne, Parodontax, Polident, Poligrip, Aquafresh), vitamins and supplements (Centrum, Caltrate, Emergen-C), pain relief (Advil, Panadol, Voltaren), respiratory health (Otrivin, Theraflu, Robitussin), and digestive health (Nexium Control, Tums). The company's strategy is to build global scale in a small number of category-leading brands rather than operate a large number of smaller brands.
Who owns Haleon?
Haleon plc is a publicly traded company with no controlling shareholder. At the time of the July 2022 demerger, GSK plc and Pfizer Inc. each retained significant stakes in Haleon, but both companies have been reducing their positions over time. As of early 2026, both GSK and Pfizer have substantially reduced their stakes. The remaining shares are held by institutional investors and public shareholders. The company's board includes a majority of independent non-executive directors.
- Founded: 2022
- Headquarters: Weybridge, Surrey, United Kingdom
- Company Type: Publicly Traded
- Stock: LSE: HLN
Where Is Voltaren Made / Based?
- Headquarters: Weybridge, United Kingdom
- Manufacturing / Operations: United Kingdom, Germany, United States, Mexico
Brands Owned by Haleon plc
Voltaren Ownership: Pros & Cons
Advantages
- +Effective anti-inflammatory pain relief for various conditions
- +Available in multiple formulations including topical options
- +Trusted brand reputation built over decades
- +Strong distribution network reaching retailers worldwide
- +Backed by Novartis's research capabilities and pharmaceutical expertise
- +Topical formulations allow localized pain relief with fewer systemic effects
- +Affordable pricing making pain relief accessible
Considerations
- -Potential gastrointestinal side effects with oral formulations
- -Not suitable for patients with certain health conditions
- -Competition from other pain relief and anti-inflammatory brands
- -Regulatory restrictions on availability in some markets
- -Potential for allergic reactions in some users
- -Long-term use may have health implications
Frequently Asked Questions About Voltaren
Where to Buy
Disclosure: We may earn commission from purchasesHaleon plc Stock Information
Jobs at Haleon plc
Latest News About Voltaren
Related Articles About Voltaren
View more articlesPharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Brand Spin-offs: When Companies Sell Off Their Own Brands
From Kenvue to Kellanova, major corporations are spinning off iconic brands into independent companies. Learn why, how it works, and what it means for consumers.
Monthly M&A Roundup: February 2026 Brand Ownership Changes
From Keurig Dr Pepper's planned split to the Netflix-WBD saga, here is every major brand ownership change and deal in February 2026.